Human C'3: evidence for the liver as the primary site of synthesis

Science
C A AlperF D Moore

Abstract

The liver is the primary, if not sole, site of synthesis of the third component of human complement, as shown by a change in the recipient from C'3 FS(0.6) to C'3 SS, the donor type, following homotransplantation of the liver.

References

May 1, 1968·Proceedings of the Society for Experimental Biology and Medicine·N KashiwagiT E Starzl
Nov 22, 1968·Science·E A Azen, O Smithies
Mar 1, 1966·The Journal of Clinical Investigation·J H Peters, C A Alper
Sep 1, 1968·The Journal of Clinical Investigation·C A Alper, R P Propp
Jul 8, 1966·Science·C A AlperF S Rosen
Dec 1, 1967·The Journal of Clinical Investigation·C A Alper, F S Rosen
May 1, 1955·Biochimica Et Biophysica Acta·P GRABAR, C A WILLIAMS
Jul 1, 1964·Proceedings of the Society for Experimental Biology and Medicine·D A MERRILLC M RILEY
Aug 19, 1964·Biochimica Et Biophysica Acta·S KRAUSS, E J SARCIONE
Feb 1, 1965·Analytical Biochemistry·C B LAURELL
Aug 1, 1965·The Journal of Experimental Medicine·U R NILSSON, H J MUELLER-EBERHARD

❮ Previous
Next ❯

Citations

Feb 11, 1998·Liver Transplantation and Surgery : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·T E Starzl
Aug 30, 1976·Human Genetics·P K Seth, S Seth
Jan 1, 1972·Humangenetik·D D FarhudH Walter
Jan 1, 1993·European Journal of Pediatrics·R SelbyR S Kendall
Jan 1, 1994·International Journal of Clinical & Laboratory Research·S Perissutti, F Tedesco
Dec 1, 1987·In Vitro Cellular & Developmental Biology : Journal of the Tissue Culture Association·M GuiguetG Mack
Jan 1, 1979·Lung·C MolinaD Wahl
Jan 1, 1995·Pathology Oncology Research : POR·Béla SchmidtGyörgy Füst
Jan 1, 1993·Immunologic Research·A R McPhaden, K Whaley
Sep 2, 2006·Cancer Immunology, Immunotherapy : CII·Brandon Stott, Mladen Korbelik
Nov 15, 1997·World Journal of Surgery·J FungT Starzl
Sep 29, 2005·Springer Seminars in Immunopathology·Steven H Sacks, Wuding Zhou
Feb 7, 2008·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Jin Hui TangKatherine Cianflone
Dec 1, 1973·The American Journal of Medicine
Jun 2, 1975·Clinica Chimica Acta; International Journal of Clinical Chemistry·G A YoungF M Parsons
Apr 1, 1981·International Journal for Parasitology·W E AguE J Soulsby
Jan 9, 1993·Lancet·T E StarzlM Michaels
Sep 1, 1992·Immunopharmacology·K WhaleyD Lappin
Jun 5, 2004·Developmental and Comparative Immunology·Kirstin W MatthewsRick A Wetsel
Oct 18, 2003·Metabolism: Clinical and Experimental·Zhunan Xia, Katherine Cianflone
Mar 13, 1971·Lancet·R S DuBoisI H Scheinberg
May 14, 1983·Lancet·J J MalatackT E Starzl
Jan 27, 2000·Immunopharmacology·P H PfeiferT E Hugli
Feb 22, 2001·Veterinary Immunology and Immunopathology·S A KaniaL B Corbeil
Mar 29, 2001·Immunology Letters·M S WrightT G Abrahamsen
Jul 1, 1995·Molecular Medicine Today·P A AndrewsS H Sacks
Sep 14, 1972·The New England Journal of Medicine·S RuddyK F Austen
Jun 6, 1974·The New England Journal of Medicine·S Ruddy, H R Colten
Mar 12, 1981·The New England Journal of Medicine·H R ColtenF S Rosen
Nov 1, 1984·The New England Journal of Medicine·G RamseyG D Lindsay
Aug 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·A S WhiteheadG Fey
Feb 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·M H de Bruijn, G H Fey

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.